Recent GILD News
- Gilead Board Director Kevin E. Lofton Named to List of Influential Leaders • Business Wire • 10/02/2023 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/30/2023 12:09:35 AM
- CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Hepatic Impairment • Business Wire • 09/19/2023 12:30:00 PM
- Kite’s Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma • Business Wire • 09/18/2023 08:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/14/2023 01:00:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/13/2023 10:50:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/12/2023 08:21:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2023 12:44:10 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2023 12:40:57 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2023 12:37:41 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2023 12:19:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2023 12:11:25 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/11/2023 08:09:02 PM
- Gilead’s Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer • Business Wire • 09/10/2023 07:01:00 AM
- Gilead Prices $2 Billion of Senior Unsecured Notes • Business Wire • 09/08/2023 12:55:00 AM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 09/07/2023 09:28:50 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/07/2023 12:29:01 PM
- Keep An Eye Out: Pre-Market Movers And Recommendations • IH Market News • 09/06/2023 12:58:56 PM
- Gilead Covid-19 Drug Cleared by FDA for Patients with Liver Disease • Dow Jones News • 08/24/2023 01:33:00 PM
- FDA Approves Veklury® (Remdesivir) to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment • Business Wire • 08/24/2023 12:30:00 PM
- Gilead Sciences to Present at Upcoming Investor Conferences • Business Wire • 08/23/2023 08:05:00 PM
- Gilead Sciences Magrolimab Studies Enrollment Paused by FDA Request • Dow Jones News • 08/21/2023 01:18:00 PM
- Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML • Business Wire • 08/21/2023 12:30:00 PM
- Gilead Sciences and Meharry Medical College Highlight Five-Year Impact of Gilead COMPASS Initiative® on HIV in the Southern United States • Business Wire • 08/18/2023 04:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2023 09:19:22 PM
Image Protect Announces Memorandum of Understanding for Pending New Business Acquisition • IMTL • Oct 2, 2023 8:14 AM
Volcon Announces First Shipment of Newly Updated Grunt EVO Electric Motorcycle Units • VLCN • Sep 29, 2023 10:16 AM
Integrated Ventures Reports $3,862,849 In Yearly Mining Revenues With 162 Bitcoins Produced • INTV • Sep 29, 2023 10:00 AM
Branded Legacy Inc. Unveils Exciting Q4 2023 Milestones and Forges Ahead with Key Partnerships • BLEG • Sep 28, 2023 10:44 AM
UC Asset Signed MOU with Tenant to Build 8000 sq ft Cannabis Property • UCASU • Sep 28, 2023 9:00 AM
Goldshore Summer Field Program Identifies Five New Gold Trends Including Two High Grade Copper-Gold Trends • GSHRF • Sep 28, 2023 8:03 AM